[go: up one dir, main page]

WO1997020554B1 - Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc - Google Patents

Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc

Info

Publication number
WO1997020554B1
WO1997020554B1 PCT/US1996/019447 US9619447W WO9720554B1 WO 1997020554 B1 WO1997020554 B1 WO 1997020554B1 US 9619447 W US9619447 W US 9619447W WO 9720554 B1 WO9720554 B1 WO 9720554B1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
compound
formula
treatment
cns
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/019447
Other languages
English (en)
Other versions
WO1997020554A1 (fr
Filing date
Publication date
Priority claimed from US08/567,199 external-priority patent/US5646180A/en
Priority to UA98073527A priority Critical patent/UA61902C2/uk
Priority to EP96942917A priority patent/EP0866696B1/fr
Priority to KR1019980704028A priority patent/KR19990071750A/ko
Priority to HU9903673A priority patent/HUP9903673A3/hu
Priority to JP9521449A priority patent/JP2000501713A/ja
Priority to AU11486/97A priority patent/AU722850B2/en
Priority to BR9611861A priority patent/BR9611861A/pt
Priority to DE69633680T priority patent/DE69633680T2/de
Priority to PL96327061A priority patent/PL187747B1/pl
Application filed filed Critical
Priority to DK96942917T priority patent/DK0866696T3/da
Priority to APAP/P/1998/001340A priority patent/AP864A/en
Priority to AT96942917T priority patent/ATE279922T1/de
Priority to NZ324603A priority patent/NZ324603A/xx
Publication of WO1997020554A1 publication Critical patent/WO1997020554A1/fr
Publication of WO1997020554B1 publication Critical patent/WO1997020554B1/fr
Priority to NO19982556A priority patent/NO317837B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Procédés et compositions de traitement des effets du VIH sur le système nerveux central, notamment de la démence liée au SIDA.
PCT/US1996/019447 1995-12-05 1996-12-05 Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc Ceased WO1997020554A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
UA98073527A UA61902C2 (en) 1995-12-05 1996-05-12 Vx-478 as active ingredient of pharmaceutical composition for decreasing virus infection in central nervous system and method for treatment using this composition
NZ324603A NZ324603A (en) 1995-12-05 1996-12-05 Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC
DK96942917T DK0866696T3 (da) 1996-12-05 1996-12-05 Behandling af HIV ZNS-effekter med VX-478 alene eller i kombination med AZT eller 3TC
HU9903673A HUP9903673A3 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc
JP9521449A JP2000501713A (ja) 1995-12-05 1996-12-05 Ｖｘ―４７８を単独でまたはａｚｔか３ｔｃと組み合わせて使用したｈｉｖのｃｎｓ作用の治療法
AU11486/97A AU722850B2 (en) 1995-12-05 1996-12-05 Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC
BR9611861A BR9611861A (pt) 1995-12-05 1996-12-05 Tratamento dos efeitos sobre o sistema nervoso central do hiv com vx-478 sozinho ou em combinação com azt ou 3tc
DE69633680T DE69633680T2 (de) 1995-12-05 1996-12-05 Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc
PL96327061A PL187747B1 (pl) 1995-12-05 1996-12-05 Zastosowanie sulfonamidowego inhibitora proteazy HIV
EP96942917A EP0866696B1 (fr) 1995-12-05 1996-12-05 Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc
KR1019980704028A KR19990071750A (ko) 1995-12-05 1996-12-05 Vx-478 단독으로 또는 지도부딘이나 3tc와 함께 vx-478을사용하여 인체 면역 결핍 비루스의 중추 신경계 효과를치료하는 방법
APAP/P/1998/001340A AP864A (en) 1995-12-05 1996-12-05 Treatment of the cns effects of HIV with VX-478, alone or in combination with azt or 3tc.
AT96942917T ATE279922T1 (de) 1995-12-05 1996-12-05 Behandlung von zns-wirkungen des hiv mit vx-478, allein oder kombiniert mit azt oder 3tc
NO19982556A NO317837B1 (no) 1995-12-05 1998-06-04 Anvendelse av forbindelse for fremstilling av et medikament for a inhibere et aspartylproteaseavhengig virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 1995-12-05
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV

Publications (2)

Publication Number Publication Date
WO1997020554A1 WO1997020554A1 (fr) 1997-06-12
WO1997020554B1 true WO1997020554B1 (fr) 1997-08-07

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/019447 Ceased WO1997020554A1 (fr) 1995-12-05 1996-12-05 Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc

Country Status (23)

Country Link
US (1) US5646180A (fr)
EP (1) EP0866696B1 (fr)
JP (1) JP2000501713A (fr)
KR (1) KR19990071750A (fr)
CN (1) CN1203530A (fr)
AP (1) AP864A (fr)
AT (1) ATE279922T1 (fr)
AU (1) AU722850B2 (fr)
BR (1) BR9611861A (fr)
CA (1) CA2238471A1 (fr)
CZ (1) CZ291994B6 (fr)
DE (1) DE69633680T2 (fr)
ES (1) ES2231828T3 (fr)
HU (1) HUP9903673A3 (fr)
NO (1) NO317837B1 (fr)
NZ (1) NZ324603A (fr)
OA (1) OA10691A (fr)
PL (1) PL187747B1 (fr)
PT (1) PT866696E (fr)
RU (1) RU2203658C2 (fr)
UA (1) UA61902C2 (fr)
WO (1) WO1997020554A1 (fr)
ZA (1) ZA9610139B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DE69718168T2 (de) * 1996-06-25 2003-10-23 Glaxo Group Ltd., Greenford Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
EP0938321B1 (fr) * 1996-06-25 2004-01-14 Glaxo Group Limited Combinaisons comprenant du vx478, de la zidovudine et du 3tc pouvant etre utilisees dans le traitement du vih
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
BR9809124A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
WO1998057648A1 (fr) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
ATE319712T1 (de) 1999-12-21 2006-03-15 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
DE60142131D1 (de) * 2000-10-16 2010-06-24 Conor Medsystems Inc Expandierbare medizinische Vorrichtung zur Freisetzung eines Heilmittels
JP2005500988A (ja) 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
EP1490090A4 (fr) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
ES2720618T3 (es) 2004-07-27 2019-07-23 Gilead Sciences Inc Análogos de fosfonato de compuestos de inhibidores de VIH
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
EP1976976A4 (fr) * 2005-12-23 2010-12-15 Univ Rochester Traitement du neuro-sida a l'aide d'inhibiteurs de glycogene synthase kinase (gsk)-3
MX2008013434A (es) * 2006-04-19 2009-01-26 Abbott Gmbh & Co Kg Arilsufonas heterociclicas adecuadas para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6.
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US9789012B2 (en) 2014-02-28 2017-10-17 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (fr) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv et mogroside v utilisables en tant qu'agonistes/stimulateurs/agents de déblocage des récepteurs toll 4 et adjuvant destiné à être utilisé dans un vaccin humain/animal et pour stimuler l'immunité contre des agents pathologiques
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
WO2017048727A1 (fr) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll pour le traitement du vih
WO2018112229A1 (fr) 2016-12-14 2018-06-21 Eam Corporation Stratifiés absorbants, noyaux absorbants et articles jetables utilisant les stratifiés absorbants, et procédés associés
EP3801424B1 (fr) 2018-05-28 2025-01-22 Attends Healthcare Products, Inc. Stratifié à couche de siccité pour articles absorbants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Similar Documents

Publication Publication Date Title
WO1997020554B1 (fr) Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
CA2192433A1 (fr) Composes anti-herpesvirus et methodes de caracterisation, de production et d'utilisation
RU98112594A (ru) Лечение поражения центральной нервной системы, вызванного вич, с помощью vx-478, изолированно либо в комбинации с azt или зтс
CA2378148A1 (fr) Trifluorobutenes nematicides
ATE392895T1 (de) Verwendung von ritonavir (abt-538) zur verbesserung der pharmakokinetik von arzneimitteln, die durch cytochrom p450 metabolisiert werden, im rahmen einer behandlung von aids
CA2067381A1 (fr) Traitement des infections a vih et composes utiles a cet egard
NZ324603A (en) Treatment of the CNS effects of HIV with VX-478, alone or in combination with AZT or 3TC
CA2075173A1 (fr) Composes et methodes pour inhiber le vih et les virus associes
CA2168447A1 (fr) Composes et methodes pour l'inhibition du vih et de virus connexes
IN2012DE00109A (fr)
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
AU2838497A (en) Process for the preparation of substituted aryllactic acid- containing cyclodepsipeptides having 24 ring atoms
AU3855297A (en) Pharmaceutical composition for treating papillomavirus tumours and infection
CA2041818A1 (fr) Separation des enantiomeres du cimaterol, (-)-cimaterol et leur usage comme composes pharmaceutiques ou comme stimulateurs du rendement
ATE157988T1 (de) Neuartige prolyl-endopeptidase-inhibitoren sna- 115 und sna-115t, ihre herstellung, und hierbei verwendete stämme
RU94039284A (ru) Производные пиперазина, способ их получения, фармкомпозиция и ее использование
WO1995014011A3 (fr) Derives de la 5,6-dihydropyrone en tant qu'inhibiteurs de la protease et agents antiviraux
UA74324C2 (uk) Форми кристалічного ефавіренцу та способи лікування з їх допомогою
WO1998027930A3 (fr) Nouvelle utilisation des derives d'aminopiperazine
CA2182675A1 (fr) Compositions d'elimination des depots de calcaire
EP1690545A3 (fr) Préparation du Product R et produit ainsi obtenu
ES2054011T3 (es) Un proceso para la preparacion de un compuesto, "leualacina".
EP0739901A3 (fr) Dérivés d'oligoribonucléotides et leur application comme agents antiviraux
CA2228939A1 (fr) Agents endoparasiticides a base de didepsipeptides, nouveaux didepsipeptides et leur procede de preparation